Actavis eyes fast-growing biosimilar market

With a deal on the table to buy up a 51% stake in Poland's Bioton, Actavis says it wants to use the move as a springboard into biosimilars. Like a slate of biopharma companies, the Icelandic generic drugmaker sees a big future for companies with the financial wherewithal to develop a new generation of biologics that act in a similar fashion to some of the world's biggest biotech blockbusters. Analysts expect the biosimilar market to hit $10 billion by 2015, but it won't be cheap or easy gaining regulatory approvals. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.